194 related articles for article (PubMed ID: 34664092)
1. Prognostic factors in children and adolescents with differentiated thyroid carcinoma treated with total thyroidectomy and RAI: a real-life multicentric study.
Cistaro A; Quartuccio N; Garganese MC; Villani MF; Altini C; Pizzoferro M; Piccardo A; Cabria M; Massollo M; Maghnie M; Campennì A; Siracusa M; Baldari S; Panareo S; Urso L; Bartolomei M; De Palma D; Grossi A; Mazzoletti A; Dondi F; Bertagna F; Giubbini R; Albano D
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1374-1385. PubMed ID: 34664092
[TBL] [Abstract][Full Text] [Related]
2. Combination of Stimulated Thyroglobulin and Antithyroglobulin Antibody Predicts the Efficacy and Prognosis of
Pan M; Li Z; Jia M; Lu X
Front Endocrinol (Lausanne); 2022; 13():857057. PubMed ID: 35464061
[TBL] [Abstract][Full Text] [Related]
3. Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine.
Nóbrega G; Cavalcanti M; Leite V; Vilar L; Brandão SCS
Endocrine; 2022 Jun; 76(3):642-647. PubMed ID: 35237910
[TBL] [Abstract][Full Text] [Related]
4. Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study.
Han N; Lu C; Li J; Wang C; Zhao Z; Zhang Y; Liu X; Si Z; Wang G; Wang Z; Li F; Wang X
Front Endocrinol (Lausanne); 2023; 14():1222470. PubMed ID: 37810895
[TBL] [Abstract][Full Text] [Related]
5. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
6. Factors Influencing the Success of the First Radioiodine Therapy for Differentiated Thyroid Carcinoma.
Claimon A; Pusuwan P; Khiewvan B
J Med Assoc Thai; 2017 Feb; 100(2):207-18. PubMed ID: 29916638
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of ATA Low-Risk Pediatric Thyroid Cancer Patients Not Treated With Radioactive Iodine Therapy.
Bojarsky M; Baran JA; Halada S; Isaza A; Zhuang H; States L; Grant FD; Robbins S; Sisko L; Ricarte-Filho JC; Kazahaya K; Adzick NS; Mostoufi-Moab S; Bauer AJ
J Clin Endocrinol Metab; 2023 Nov; 108(12):3338-3344. PubMed ID: 37265226
[TBL] [Abstract][Full Text] [Related]
8. Improving the prediction of persistent and recurrent differentiated thyroid cancer using the American Thyroid Association 2015 risk stratification system.
Markantes GK; Karakioulaki M; Papanikolopoulou S; Theodoropoulou A; Markou KB; Vagenakis AG; Spyridonidis T; Goulis DG; Michalaki MA
Hormones (Athens); 2021 Dec; 20(4):761-768. PubMed ID: 34383288
[TBL] [Abstract][Full Text] [Related]
9. Early preablation rhTSH-stimulated thyroglobulin predicts outcome of differentiated thyroid cancer (DTC) patients.
Campennì A; Ruggeri RM; Siracusa M; Comis AD; Romano D; Vento A; Lanzafame H; Capoccetti F; Alibrandi A; Baldari S; Giovanella L
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2466-2475. PubMed ID: 33416957
[TBL] [Abstract][Full Text] [Related]
10. Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients' Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial.
Jammah AA; Masood A; Akkielah LA; Alhaddad S; Alhaddad MA; Alharbi M; Alguwaihes A; Alzahrani S
Front Endocrinol (Lausanne); 2020; 11():603432. PubMed ID: 33716951
[TBL] [Abstract][Full Text] [Related]
11. Thyroglobulin levels before radioactive iodine therapy and dynamic risk stratification after 1 year in patients with differentiated thyroid cancer.
Bandeira L; Padovani RDP; Ticly AL; Cury AN; Scalissi NM; Marone MMS; Ferraz C
Arch Endocrinol Metab; 2017 Dec; 61(6):590-599. PubMed ID: 29412384
[TBL] [Abstract][Full Text] [Related]
12. Radioactive Iodine Therapy Decreases the Recurrence of Intermediate-Risk PTC With Low Thyroglobulin Levels.
Tian T; Qi Z; Huang S; Wang H; Huang R
J Clin Endocrinol Metab; 2023 Jul; 108(8):2033-2041. PubMed ID: 36715264
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of 12-month response to therapy in pediatric patients with differentiated thyroid cancer.
Zampella E; Piscopo L; Manganelli M; Volpe F; Nappi C; Gaudieri V; Pace L; Schlumberger M; Cuocolo A; Klain M
Endocrine; 2023 Jun; 80(3):612-618. PubMed ID: 36692657
[TBL] [Abstract][Full Text] [Related]
14. The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer.
Albano D; Dondi F; Zilioli V; Panarotto MB; Galani A; Cappelli C; Bertagna F; Giubbini R; Casella C
Ann Nucl Med; 2021 Oct; 35(10):1089-1099. PubMed ID: 34152569
[TBL] [Abstract][Full Text] [Related]
15. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
[TBL] [Abstract][Full Text] [Related]
16. Intermediate-risk thyroid carcinoma: indicators of a poor prognosis.
Faro FN; Bezerra ÂMLB; Scalissi NM; Cury AN; Marone MM; Ferraz C; do Prado Padovani R
Arch Endocrinol Metab; 2021 May; 64(6):764-771. PubMed ID: 34033287
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of pre-ablation stimulated thyroglobulin as predictors of disease persistence.
Karapanou O; Tzanela M; Rondogianni P; Dacou-Voutetakis C; Chiotis D; Vlassopoulou B; Vassiliadi D; Kanaka-Gantenbein C; Tsagarakis S
Endocrine; 2020 Dec; 70(3):566-574. PubMed ID: 32533509
[TBL] [Abstract][Full Text] [Related]
18. Thyroglobulin/thyrotropin ratio for predicting long-term response in differentiated thyroid carcinoma: a retrospective study.
De Marchi AF; de Macedo ABT; Soares CSP; Bolfi F; Iessi MRG; de Oliveira CC; Koga KH; Moriguchi SM; Tagliarini JV; da Silva Mazeto GMF
Arch Endocrinol Metab; 2021 Nov; 65(4):428-435. PubMed ID: 34283903
[TBL] [Abstract][Full Text] [Related]
19. Metastatic differentiated thyroid cancer with negative serum stimulated Tg but positive post-therapeutic
Li X; Li H; Yan Y; Xu H; Wang Y; Liu Y; Gao R
Endocrine; 2023 Oct; 82(1):117-125. PubMed ID: 37209260
[TBL] [Abstract][Full Text] [Related]
20. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
